Fineschi N, Cavalieri F, Garelick H, Prugnola A, Pellegrini V, Zuckerman A J
Sclavo Research Center and R/D Vaccines, Siena, Italy.
J Hepatol. 1991;13 Suppl 4:S146-51. doi: 10.1016/0168-8278(91)90048-g.
A novel isolate of hepatitis A virus, obtained from a clinical sample, has been adapted to grow on cultured human diploid cells. Growth and purification parameters have been optimized to obtain conditions suitable for the development of an inactivated vaccine. The entire viral genome was molecularly cloned, and the gene encoding the VP3 capsid protein was expressed in Escherichia coli. The resulting recombinant VP3 was used to obtain rabbit antisera which recognize the denatured protein in purified virion preparations. Nucleotide sequencing data are presented and compared to known sequences of different strains.
从一份临床样本中分离出的一株新型甲型肝炎病毒已适应在培养的人二倍体细胞上生长。生长和纯化参数已得到优化，以获得适合开发灭活疫苗的条件。整个病毒基因组进行了分子克隆，编码VP3衣壳蛋白的基因在大肠杆菌中表达。所得重组VP3用于制备兔抗血清，该抗血清可识别纯化病毒粒子制剂中的变性蛋白。文中给出了核苷酸测序数据，并与不同毒株的已知序列进行了比较。
